Previous researches and our study, which illuminate the antitumoral effect of GSK-J4 by inhibiting KDM6B activity, indicate that a KDM6B-based target therapy is emerging as a promising cancer therapy for various tumors, including PCa. Here, KDM6B is linked to cancer.